A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

NCT00185094 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension
Insulin Resistance
Metabolic Syndrome

Interventions

DRUG: Olmesartan medoxomil
DRUG: Losartan potassium
DRUG: Atenolol

Sponsor

Daiichi Sankyo